Christopher Keenan joined Pliant Therapeutics as Vice President, Investor Relations and Corporate Communications in November 2020 with responsibility for implementing strategic investor relations initiatives for Pliant and our shareholders. Mr. Keenan brings over 20 years of investor relations/ corporate communications experience having served in the role in small to large market capitalized public companies within the pharmaceutical, biotechnology, medical device, and specialty pharmaceutical industries.
Prior to Pliant, Mr. Keenan was Vice President, Investor Relations and Corporate Communications at CytomX Therapeutics. He began his investor relations career at Isis Pharmaceuticals (now Ionis Pharmaceuticals). He began his professional career at The Weinberg Group, a scientific and regulatory consultancy to the biopharmaceutical industry.
Mr. Keenan received his B.A. in English from Kenyon College.